Improved efficacy of mesenchymal stromal cells stably expressing CXCR4 and IL-10 in a xenogeneic graft versus host disease mouse model
暂无分享,去创建一个
R. Yañez | J. Bueren | M. Fernández-García | C. Suárez-Cabrera | R. Hervás-Salcedo | M. Hernando-Rodríguez
[1] J. Pérez-Simón,et al. Mesenchymal Stromal Cells for Treating Steroid-Resistant Acute and Chronic Graft Versus Host Disease: A Multicenter Compassionate Use Experience , 2022, Stem cells translational medicine.
[2] J. Lammerding,et al. Enucleated human mesenchymal stromal cells for the homing and the delivery of therapeutic cargos in vivo , 2021, Nature Biomedical Engineering.
[3] U. Galderisi,et al. Clinical Trials Based on Mesenchymal Stromal Cells are Exponentially Increasing: Where are We in Recent Years? , 2021, Stem cell reviews and reports.
[4] J. Antin,et al. GVHD Prophylaxis 2020 , 2021, Frontiers in Immunology.
[5] R. Yañez,et al. The Current Status of Mesenchymal Stromal Cells: Controversies, Unresolved Issues and Some Promising Solutions to Improve Their Therapeutic Efficacy , 2021, Frontiers in Cell and Developmental Biology.
[6] N. Kröger,et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years , 2021, Bone Marrow Transplantation.
[7] R. Yañez,et al. Enhanced anti-inflammatory effects of mesenchymal stromal cells mediated by the transient ectopic expression of CXCR4 and IL10 , 2021, Stem cell research & therapy.
[8] A. Erbacher,et al. Long-term follow-up after the application of mesenchymal stromal cells in children and adolescents with steroid-refractory graft-versus-host disease. , 2021, Stem cells and development.
[9] G. Hill,et al. Current Concepts and Advances in Graft-Versus-Host Disease Immunology. , 2021, Annual review of immunology.
[10] E. Shpall,et al. A Phase 3 randomized study of Remestemcel-L versus placebo added to second line therapy in patients with steroid refractory acute graft versus host disease. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[11] M. Mohty,et al. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. , 2020, The New England journal of medicine.
[12] J. Laffey,et al. Overexpression of IL-10 Enhances the Efficacy of Human Umbilical-Cord-Derived Mesenchymal Stromal Cells in E. coli Pneumosepsis , 2019, Journal of clinical medicine.
[13] L. Kanz,et al. Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation , 2019, Bone Marrow Transplantation.
[14] Xiangbei Qi,et al. Treatment of Type II Collagen-Induced Rat Rheumatoid Arthritis Model by Interleukin 10 (IL10)-Mesenchymal Stem Cells (BMSCs) , 2019, Medical science monitor : international medical journal of experimental and clinical research.
[15] H. Lazarus,et al. Allogeneic hematopoietic cell transplantation; the current renaissance. , 2019, Blood reviews.
[16] Haitao Du,et al. Mesenchymal stem cells and CXC chemokine receptor 4 overexpression improved the therapeutic effect on colitis via mucosa repair , 2018, Experimental and therapeutic medicine.
[17] L. Dong,et al. Mesenchymal Stem Cells Inhibited Dendritic Cells Via the Regulation of STAT1 and STAT6 Phosphorylation in Experimental Autoimmune Uveitis. , 2018, Current molecular medicine.
[18] N. Arsenijević,et al. Mesenchymal stem cells protect from acute liver injury by attenuating hepatotoxicity of liver natural killer T cells in an inducible nitric oxide synthase‐ and indoleamine 2,3‐dioxygenase‐dependent manner , 2018, Journal of tissue engineering and regenerative medicine.
[19] Anoop Babu Vasandan,et al. Human Mesenchymal stem cells program macrophage plasticity by altering their metabolic status via a PGE2-dependent mechanism , 2016, Scientific Reports.
[20] K. Ozawa,et al. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study , 2016, International Journal of Hematology.
[21] E. Andreu,et al. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[22] H. Li,et al. Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10 , 2014, Leukemia.
[23] F. Nestle,et al. Xenogeneic Graft-versus-Host-Disease in NOD-scid IL-2Rγnull Mice Display a T-Effector Memory Phenotype , 2012, PloS one.
[24] G. Pizzolo,et al. Toll‐Like Receptor‐3‐Activated Human Mesenchymal Stromal Cells Significantly Prolong the Survival and Function of Neutrophils , 2011, Stem Cells.
[25] Z. Madeja,et al. Genetically modified adipose tissue-derived mesenchymal stem cells overexpressing CXCR4 display increased motility, invasiveness, and homing to bone marrow of NOD/SCID mice. , 2011, Experimental hematology.
[26] J. Scheller,et al. The pro- and anti-inflammatory properties of the cytokine interleukin-6. , 2011, Biochimica et biophysica acta.
[27] C. Jorgensen,et al. Mesenchymal Stem Cells Inhibit Human Th17 Cell Differentiation and Function and Induce a T Regulatory Cell Phenotype , 2010, The Journal of Immunology.
[28] A. Uccelli,et al. Mesenchymal stem cells in health and disease , 2008, Nature Reviews Immunology.
[29] E. Riley,et al. IL-10: The Master Regulator of Immunity to Infection , 2008, The Journal of Immunology.
[30] L. Ou,et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[31] C. Min,et al. IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation , 2007, Bone Marrow Transplantation.
[32] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[33] Moustapha Hassan,et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.
[34] M. Jordana,et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. , 1998, The Journal of clinical investigation.
[35] M. Scarsella,et al. Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells. , 2015, Stem cells and development.
[36] D. Prockop,et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.